Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Recludix Inks $1.3B Deal with Sanofi.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): CLEMETSON, JEFF
- Source:
San Diego Business Journal. 7/31/2023, Vol. 44 Issue 31, p1-22. 2p.
- Subject Terms:
- Additional Information
- Subject Terms:
- Abstract:
The article aims on Recludix Pharma collaborates with Sanofi to develop oral STAT6 inhibitors for immune and inflammatory diseases. Their innovative platform targeting SH2 domains gains attention and investment, offering potential treatments for various ailments, including dermatological conditions, respiratory diseases, psoriasis, Crohn's Disease, rheumatoid arthritis, multiple sclerosis and cancer.
No Comments.